AKA.A. Kuznetsova

A.A. Kuznetsova

*This is an algorithmically generated author record based on publicly available information.

A.A. Kuznetsova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • TSH and β-hCG levels in patients with placenta accreta spectrum

    by A.A. Kuznetsova, Saint Petersburg 2B Akkuratova Str., E.S. Shelepova, K.A. Alfimova, O.I. Labushnyak, N.A. Osipova, I.E. Zazerskaya

    Aim. To assess the concentration of thyroid-stimulating hormone and human chorionic gonadotropin in pregnant women with placenta accreta spectrum. Design. Longitudinal prospective case-control study. Materials and methods. The study included 161 patients with placenta accreta spectrum (main group further devided in accordance with presence of ceserian ssction (CS) scar (subgroup 1.1 with CS scar present, n = 143 and subgroup 1.2 with CS scar absent, n = 18), 126 patients previously underwent cesarean section (comparison group 1), and 36 healthy patients (comparison group 1). Patients in all groups were further divided by the presence of established thyroid pathology. A comparative analysis was performed to evaluate thyroid-stimulating hormone levels during pregnancy and human chorionic gonadotropin levels based on the first timester screening. Results. According to the study results, among patients without thyroid pathology, a significant decrease of thyroid stimulating hormone was noted in the 1st and 3rd trimesters in main group, relative to comparison groups (p1.1–1 = 0.019; 0.014; p1.2–2 = 0.03; 0.024). No significant difference in the levels of human chorionic gonadotropin was found in the groups (both absolute and standardized values (abs/MoM)) (p1.1–1 = 0.863/0.591; p1.2–2 = 0.286/0.987). The concentration of thyroid stimulating hormone in the 1st trimester significantly correlated with placenta previa (p1.1–1 = 0.009; p1.2–2 = 0.036). The average daily dosage of levothyroxine sodium in the main group was significantly higher than in the comparison groups (p1 = 0.007; p2 = 0.006). Conclusion. Thyroid-stimulating hormone levels in the first and third trimesters in patients without established thyroid pathology are reduced and correlate with the presence of placenta accreta spectrum. Meanwhile, patients with placenta accreta require higher doses of hormone replacement therapy during pregnancy, with no significant correlation between thyroid-stimulating hormone levels and the presence of this complication. Keywords: placenta accreta spectrum, TSH, hCG.